Introduction {#Sec1}
============

Type 1 diabetes is a common autoimmune disorder that arises by an interaction between genes and the environment. To date, ten loci have been identified including the HLA class II genes, the cytotoxic T-lymphocyte associated protein 4 (*CTLA4*) locus, protein tyrosine phosphatase, non-receptor type 22 (lymphoid) (*PTPN22*), IL-2 receptor, alpha (*IL2RA*), interferon induced with helicase C domain 1 (*IFIH1*) and four novel loci identified by a genome-wide association study \[[@CR1]\].

The protein products of these genes play important roles in antigen presentation and the cellular immune response, highlighting the importance of the immune system in the pathogenesis of type 1 diabetes. However, not all patients with evidence of islet autoimmunity develop complete beta cell failure \[[@CR2]\]. Given the evidence to suggest that early weight gain and growth in childhood are associated with type 1 diabetes \[[@CR3]\], it is possible that factors influencing insulin action (body weight and fat mass) and islet function may predispose to or influence the presentation of type 1 diabetes.

Lower IGF-1 concentrations predict the development of glucose intolerance in adults \[[@CR4]\]. George et al. reported that islet overexpression of *IGF1* in diabetic mice enabled islet regeneration and gradual correction of hyperglycaemia and hypoinsulinaemia \[[@CR5]\]. A microsatellite in the region 5′ to *IGF1* has been associated with adult height, cardiovascular risk, osteoporosis and type 2 diabetes in some \[[@CR6]\] but not all \[[@CR7]\] studies.

Since common variation in *IGF1* could alter circulating IGF-1 concentrations and therefore body habitus, insulin action and beta cell secretion, we sought to determine the associations, if any, between *IGF1* and circulating IGF-1 concentrations, size at birth, both fasting and postprandial insulin concentrations, and type 1 diabetes.

Materials and methods {#Sec2}
=====================

Polymorphism identification {#Sec3}
---------------------------

DNA samples from 32 randomly selected type 1 diabetic probands were amplified using specifically designed forward and reverse primers. This provided 88% probability of detecting single nucleotide polymorphisms (SNPs) with minor allele frequencies (MAF) of 0.033, 96% probability for MAF 0.05 and 99.8% for MAF 0.10 \[[@CR8]\]. Resequencing included the 3 kb region 5′ to the gene, all exons and exon--intron boundaries and 3′ untranslated region. Four 1 kb segments in the second intron, \~10 kb intervals apart, were also resequenced.

Tag-SNP selection {#Sec4}
-----------------

The resequencing genotype data were used to select SNP subsets that predicted the genotypes of the remainder, using a coefficient of determination, *R*^2^, which measures the ability to predict each known SNP genotype by linear regression on the tag-SNP genotypes \[[@CR9]\]. We considered only SNPs with a MAF ≥ 0.10 in the type 1 diabetes collection and ≥0.05 in the Avon Longitudinal Study of Parents And Children (ALSPAC) cohort (for details see below and Electronic supplementary material \[[ESM](#MOESM6){ref-type=""}\]), using a minimum *R*^2^ of 0.8.

Genotyping {#Sec5}
----------

All genotyping data were double-scored to minimise error. All genotypes were in Hardy--Weinberg equilibrium (*p* \> 0.05).

Populations studied {#Sec6}
===================

All DNA samples were collected after ethics approval and informed consent had been obtained.

**Type 1 diabetes family collection** Type 1 diabetes families were of white European descent, with two parents and at least one affected child. The populations studied have been described previously \[[@CR8]\].

**ALSPAC** Details of this birth cohort are available on the ALSPAC website ([www.alspac.bris.ac.uk](http://www.alspac.bris.ac.uk)). The children in this study are from a 10% 'Children in Focus' sub-cohort (1,335 full-term singleton infants) randomly selected from the last 6 months of recruitment for more detailed measurements of growth. Birthweight was noted from hospital records, and length and head circumference were measured after birth. At age 7 years (mean age 7.5 ± 0.1 years), body weight and height were measured. Body composition was assessed at age 9 years by whole-body dual-energy X-ray absorptiometry. Internal SD scores were calculated for all parameters of growth to adjust for age and sex. IGF-1 concentrations were measured in cord blood samples (birth) and in venous blood (7 or 8 years of age). Fasting insulin sensitivity was assessed by the homeostatic model assessment index ([www.dtu.ox.ac.uk/homa/](http://www.dtu.ox.ac.uk/homa/)) and insulin secretion at 30 min post oral glucose by the insulinogenic index at age 8 years.

Statistical analysis {#Sec7}
--------------------

All statistical analyses to test the association between *IGF1* and type 1 diabetes were performed in either Stata ([www.stata.com/](http://www.stata.com/)) or R ([www.r-project.org/](http://www.r-project.org/)) statistical systems. Additional routines may be downloaded ([www-gene.cimr.cam.ac.uk/clayton/software/](http://www-gene.cimr.cam.ac.uk/clayton/software/)). Missing tag-SNP genotypes were imputed under the null hypothesis and were analysed using a multilocus test \[[@CR9]\]. The microsatellite, 5′ *IGF1* CA repeat, was analysed using TRANSMIT \[[@CR10]\]. The global effect of the *IGF1* tag-SNP set on each outcome variable was entered into a multi-locus regression model. *R*^2^ change was taken as the contribution to the total variation in each outcome. Associations of *IGF1* SNPs with growth and metabolic phenotypes were analysed using univariate ANOVA (general linear models). The association of the 5′ *IGF1* CA repeat was analysed by comparing the wild-type allele (192 bp) to all other alleles \[[@CR6], [@CR7]\].

For further details on [Materials and methods](#Sec2){ref-type="sec"} section, see ESM.

Results {#Sec8}
=======

Genetic variation in *IGF1* {#Sec9}
---------------------------

Resequencing identified 27 novel polymorphisms consisting of 24 SNPs, one rare non-synonymous SNP in exon 3 (Ala to Thr) and two deletion/insertion polymorphisms. Eleven SNPs had a MAF \> 0.05. Four tag-SNPs (Table [1](#Tab1){ref-type="table"}) were selected and genotyped in the type 1 diabetes families studied. In ALSPAC, seven tag-SNPs were selected (ESM Table [1](#MOESM1){ref-type=""}). Table 1A summary of *IGF1* tag-SNPs genotyped in 2,396 familiesParameterTag-SNPrs35140968^a^rs6214rs3730220s6219SequenceAAATAACT\[-/AT\]CTCAAATAGACTTAAC\[A/G\]TGTTTTCTCAGGTTGG\[A/T\]CTCAAACTAACCTCAA\[A/G\]CTGTCTACAllele coding, 1 (minor)/2Ins/DelA/GT/AA/GMAF in parents0.2770.4430.4930.0769Minor allele transmissionsTransmitted8151309915446Untransmitted^b^7901386942446Genotype 2/2Transmitted1,150 (53.1)947 (33.3)798 (33.0)2,501 (84.8)Untransmitted^b^3,478 (53.6)2,724 (31.9)2,352 (32.47,489 (84.6)Genotype 2/1Transmitted849 (39.2)1,382 (48.5)885 (36.6)423 (14.3)Untransmitted^b^2,541 (39.1)4,226 (49.5)2,685 (37.0)1,297 (14.7)Genotype 1/1Transmitted166 (7.7)519 (18.2)737 (30.5)27 (0.91)Untransmitted^b^476 (7.3)1,594 (18.7)2,223 (30.6)67 (0.8)OR for minor allele (95% CI)1.03 (0.93--1.14)0.94 (0.87--1.01)0.97 (0.89--1.06)1.00 (0.88--1.14)^a^Deletion/insertion polymorphism^b^Untransmitted (pseudocontrol) genotypes are estimated as previously described \[[@CR8]\]Multilocus test *p* = 0.425

*IGF1* and type 1 diabetes {#Sec10}
--------------------------

The selected tag-SNPs were genotyped in 2,439 families (3,121 parent--child trios). The multilocus test of the *IGF1* tag-SNPs provided no evidence of an association with type 1 diabetes (*χ*~4~^2^ = 4.4; *p* = 0.356; Table [1](#Tab1){ref-type="table"}). The microsatellite, 5′ *IGF1* CA repeat, was genotyped in 2,109 families and analysed using TRANSMIT \[[@CR10]\]. There was no evidence of association (*p* = 0.358) (ESM Table [2](#MOESM2){ref-type=""}).

Wellcome Trust Case Control Consortium data {#Sec11}
-------------------------------------------

We used data from the Wellcome Trust Case Control Consortium (WTCCC) genome-wide association study \[[@CR1]\] to test association of the extended *IGF1* region with type 1 diabetes. The region contained 22 SNPs. When the WTCCC data were analysed using a logistic regression model adjusted for variation in allele frequencies across Great Britain, no evidence of association of these SNPs within the region was found (ESM Table [3](#MOESM3){ref-type=""}).

Association with IGF-1 concentrations {#Sec12}
-------------------------------------

In the ALSPAC children, multilocus regression models showed that the *IGF1* tag-SNP set was associated with IGF-1 protein levels at birth (*R*^2^ = 0.063; *p* = 0.029) and weakly associated at age 7 to 8 years (*R*^2^ = 0.030; *p* = 0.055; ESM Table [4](#MOESM4){ref-type=""}). Results of IGF-1 protein level associations with individual SNPs are shown in Table [2](#Tab2){ref-type="table"}. However, the multilocus *IGF1* tag-SNP set did not associate with any other childhood growth or metabolic phenotype (ESM Table [4](#MOESM4){ref-type=""}). No associations were observed between the *IGF1* CA repeat and IGF-1 concentrations or any growth or metabolic phenotype (ESM Table [5](#MOESM5){ref-type=""}). Table 2IGF-1 protein levels (ng/ml) at birth and at age 7 or 8 years by genotypes of seven *IGF1* tag-SNPs in a representative birth cohortParameter*n*Genotype (%)*p* valuers35140968 I/D (58)I/I (35)D/D (7)  At birth31588.1 (2.8)91.1 (3.6)105.0 (8.9)0.179 7 or 8 years547147.8 (2.9)147.3 (3.9)157.4 (9.1)0.581rs6214 G/G (34)G/A (50)A/A (16)  At birth30588.6 (3.6)87.7 (3.2)102.43 (5.30)0.048 7 or 8 years556144.1 (4.0)148.9 (3.1)155.83 (5.70)0.239rs3730220 A/A (38)A/T (54)T/T (9)  Birth29994.1 (3.8)88.6 (2.9)89.6 (7.4)0.509 7 or 8 years548152.0 (3.8)145.7 (3.0)141.8 (8.1)0.331rs6219 G/G (84)\*/A (16)  Birth30091.0 (2.4)85.0 (5.7)0.329 7 or 8 years547150.1 (2.5)138.8 (5.8)0.072rs2946831 T/T (89)\*/G (11)  Birth29490.0 (2.3)95.2 (7.2)0.501 7 or 8 years541148.0 (2.4)153.9 (7.1)0.432rs3730204 T/T (97)\*/C (3)  Birth294111.3 (13.5)90.3 (2.3)0.126 7 or 8 years548173.8 (12.9)147.5 (2.3)0.046rs12579108 C/C (97)\*/A (3)  Birth30190.0 (2.2)101.4 (12.1)0.358 7 or 8 years554147.6 (2.3)176.8 (15.9)0.017Values are mean (SE) for IGF-1 concentration and per cent for genotype\*Additive models, adjusted for age and sex

Discussion {#Sec13}
==========

We used a UK birth cohort, ALSPAC, and a large family collection of type 1 diabetes to explore association with a subset of SNPs generated by in-depth resequencing of the *IGF1* locus. A subset of SNPs that effectively predicted the genotype of the remainder was subsequently genotyped in these cohorts \[[@CR9]\]. We report no evidence to support the hypothesis that genetic variation in *IGF1* is associated with major susceptibility to type 1 diabetes. However, genetic variation in this locus may modestly influence circulating IGF-1 concentrations, at least at birth and during childhood.

Prior studies examining the role of genetic variation in *IGF1* in predisposition to common human disease have focused on a microsatellite in the region 5′ to *IGF1*. This variant has been inconsistently associated with adult height and type 2 diabetes \[[@CR6], [@CR7]\]. Perplexingly, the same allele has been associated with high \[[@CR6]\] and low \[[@CR7]\] IGF-1 concentrations. It is possible that other common genetic variants, in different degrees of linkage disequilibrium with this variant, alter IGF-1 concentrations and explain the discrepancy in the published studies.

We found no association between this microsatellite and circulating IGF-1 concentrations, growth or type 1 diabetes. To exclude the possibility that other polymorphisms in the gene predispose to disease, we undertook a systematic analysis of *IGF1* gene variation using tagging SNPs \[[@CR8]\]. Our relatively large white type 1 diabetes family collection of European ancestry provided \~84% power to detect a causal allele for type 1 diabetes predisposition with MAF = 0.1 and OR of 1.2 at the 5% significance level. The study was therefore adequately powered to detect weak predisposition to type 1 diabetes conferred by *IGF1*. We did not directly examine whether these variants alter the age at diagnosis of type 1 diabetes, since there was no primary evidence of association.

The possibility remains that variation in *IGF1* could alter insulin secretion or action as well as childhood growth. Therefore, to examine these associations, we adopted the same strategy in an established birth cohort. While we demonstrate that common genetic variation in *IGF1* modestly influences circulating IGF-1 concentrations at birth and during childhood, we did not find a major contribution of *IGF1* to birthweight, growth or response to oral glucose. It remains possible that maternal *IGF1* genotypes that influence maternal metabolism might alter birth size, but they are unlikely to significantly impact on childhood growth.

In summary, this large systematic study shows that common *IGF1* variants modestly influence circulating IGF-1 concentrations at birth and during childhood. However, these variants are not associated with birthweight, childhood growth and insulin secretion or action. Moreover they do not alter type 1 diabetes risk.
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